Skip to main content

Table 5 Relationship between the mRNA expression levels and DNA amplification levels of the 20 markedly upregulated genes

From: Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy

Genes Chromosome location Normal breast tissues
(n = 6)
Breast tumors
(n = 39)
Unamplified tumors Amplified tumors pa
     Number mRNA level Number mRNA level  
CDC20 1p34.1 1,0 (0,61-1,28) 2,89 (0,39-22,65)b 38 (97,5%) 2,99 (0,54-22,65) 1 (2,5%) 0,39 NS
NEK2 1q31,2-q41 1,0 (0,44-5,23) 28,41 (2,46-137,03) 12 (30,8%) 26,55 (2,66-51,92) 27 (69,2%) 28,41 (2,46-137,03) NS
BUB1 2q14 1,0 (0,53-1,51) 5,52 (0,74-25,63) 36 (92,3%) 5,43 (0,74-25,63) 3 (7,7%) 6,39 (3,46-17,15) NS
TACC3 4p16,3 1,0 (0,54-2,08) 7,32 (1,01-29,89) 38 (97,5%) 7,09 (1,01-29,89) 1 (2,5%) 15,32 NS
CENPE 4q21-q25 1,0 (0,02-2,06) 14,59 (0,08-61,89) 38 (97,5%) 14,64 (0,08-61,89) 1 (2,5%) 5,54 NS
CCNA2 4q25-q31 1,0 (0,56-1,90) 10,39 (2,20-37,31) 36 (92,3%) 10,12 (2,2-37,31) 3 (7,7%) 22,65 (3,81-32,82) NS
CCNB1 5q12 1,0 (0,42-2,32) 4,18 (0,34-22,47) 34 (87,2%) 3,53 (0,34-18,96) 5 (12,8%) 8,88 (2,67-22,47) 0,01
UBD 6p21.3 1,0 (0,31-3,91) 4,75 (0,15-106,40) 32 (82,1%) 4,89 (0,15-106,40) 7 (17,9%) 2,93 (0,54-7,43) NS
TTK 6q13-q21 1,0 (0,71-2,08) 6,72 (0,61-44,27) 37 (94,9%) 6,72 (0,61-44,27) 2 (5,1%) 15,91 (5,85-25,96) NS
CDC2 10q21.1 1,0 (0,68-2,66) 9,52 (1,19-56,17) 34 (87,2%) 8,44 (1,19-56,17) 5 (12,8%) 17,47 (12,74-42,86) 0,03
ZWINT 10q21-q22 1,0 (0,62-1,97) 5,38 (1,08-20,70) 32 (82,1%) 4,44 (1,08-20,70) 7 (17,9%) 12,52 (4,46-18,27) 0,003
BUB1B 15q15 1,0 (0,53-1,69) 10,48 (1,35-32,33) 34 (87,2%) 9,05 (1,35-32,33) 5 (12,8%) 17,33 (10,48-27,28) 0,04
CCNB2 15q21.2 1,0 (0,64-1,95) 14,21 (2,00-68,51) 35 (89,7%) 10,15 (2,0-55,08) 4 (10,2%) 21,41 (19,34-68,51) 0,03
PLK 16p12.1 1,0 (0,60-1,87) 5,46 (0,69-35,59) 16 (41,0%) 4,49 (0,69-21,61) 23 (59,0%) 5,46 (1,24-35,59) NS
AURKB 17p13.1 1,0 (0,90-2,08) 5,82 (0,00-64,52) 39 (100%) 5,82 (0-64,52) 0 - -
BIRC5 17q25 1,0 (0,37-2,0) 14,84 (1,47-150,30) 27 (69,2%) 9,96 (1,47-49,07) 12 (30,8%) 32,31 (5,84-150,30) 0,0008
NDC80 18p11.31 1,0 (0,29-1,23) 6,28 (1,05-126,38) 34 (87,2%) 5,69 (1,05-27,22) 5 (12,8%) 27,32 (4,13-126,38) 0,03
TPX2 20q11.2 1,0 (0,59-1,48) 15,69 (1,65-117,11) 22 (56,4%) 10,26 (1,65-34,46) 17 (43,6%) 24,03 (5,45-117,11) 0,002
AURKA 20q13.2-q13.3 1,0 (0,36-1,33) 7,14 (1,46-34,22) 24 (61,5%) 5,08 (1,46-32,82) 15 (38,5%) 14,04 (3,40-34,22) 0,002
CCNB3 Xp11 1,0 (0,96-4,20) 5,65 (0,00-61,53) 33 (84,6%) 4,76 (0,00-61,53) 6 (15,4%) 11,58 (5,16-25,25) NS
  1. aMann and Whitney's U Test: amplified breast tumors vs unamplified breast tumors. NS, non significant.
  2. bMedian (range) of gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 6 normal breast tissues mRNA level was 1.